International Clinical Trial: A Phase 1, First-in-Human, Double-Blind, Placebo-Controlled Single Ascending Dose Study of MT-001 in Adult Participants

Geneva, Aug. 31 -- International Clinical Trials Registry received information related to the study (ACTRN12626001022358) titled 'A Phase 1, First-in-Human, Double-Blind, Placebo-Controlled Single Ascending Dose Study of MT-001 in Adult Participants' on Aug. 19.

Study Type: Interventional

Study Design: Purpose: Treatment Allocation: Randomised controlled trial

Primary Sponsor: Mentari Therapeutics, Inc.

Condition: Migraines Migraines Neurological - Other neurological disorders

Intervention: This is a phase 1, first-in-human (FIH), double-blind, placebo-controlled single ascending dose study. Approximately 40 adult participants will be randomized 6:2 (MT-001:placebo) in up to 5 planned dosing cohorts of 8 participants each. MT-00...